TriSalus Life Sciences, Inc.
TLSI
$6.45
-$0.55-7.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.52% | 45.50% | 46.21% | 59.00% | 67.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.52% | 45.50% | 46.21% | 59.00% | 67.91% |
| Cost of Revenue | 85.04% | 80.65% | 58.79% | 57.50% | 22.19% |
| Gross Profit | 44.26% | 40.55% | 44.29% | 59.25% | 77.76% |
| SG&A Expenses | 17.47% | 15.35% | 12.78% | 25.75% | 34.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.95% | -6.06% | -10.79% | -1.88% | 9.62% |
| Operating Income | 23.01% | 32.41% | 35.04% | 24.37% | 9.99% |
| Income Before Tax | 28.78% | 42.90% | 57.64% | 49.34% | -20.29% |
| Income Tax Expenses | -25.00% | -118.18% | -52.94% | -33.33% | -42.86% |
| Earnings from Continuing Operations | 28.78% | 42.91% | 57.64% | 49.34% | -20.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.78% | 42.91% | 57.64% | 49.34% | -20.27% |
| EBIT | 23.01% | 32.41% | 35.04% | 24.37% | 9.99% |
| EBITDA | 23.30% | 32.88% | 35.63% | 24.82% | 10.44% |
| EPS Basic | 21.26% | 55.11% | 97.07% | 96.51% | 97.75% |
| Normalized Basic EPS | 46.25% | 66.68% | 95.30% | 95.15% | 97.58% |
| EPS Diluted | 21.26% | 55.11% | 97.07% | 96.51% | 97.75% |
| Normalized Diluted EPS | 46.25% | 66.68% | 95.30% | 95.15% | 97.58% |
| Average Basic Shares Outstanding | 36.27% | 38.19% | 76.96% | 91.03% | 221.86% |
| Average Diluted Shares Outstanding | 36.27% | 38.19% | 76.96% | 91.03% | 221.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |